A federal judge just told Novo Nordisk's shareholders: go ahead, sue us.
Not the whole case. Just the part that actually hurts.
The claim? Novo may have misled investors about how its blockbuster weight-loss hopeful, CagriSema, was actually tested.
Stay with me.
CagriSema combines semaglutide (the stuff in Ozempic and Wegovy) with cagrilintide, a hormone-mimicking compound.
Investors were told to expect roughly 25% weight loss.
In December 2024, the real number came in at 20.4%.
The market didn't take it well.
They say Novo made it sound like the trial used a fixed maximum dose, just like earlier studies.
It didn't.
The trial actually let patients adjust their dose along the way.
End result: only 57% of participants ever reached the highest dose.
That's not a small technicality.
Tolerability — how well patients can stay on the max dose — is the single biggest question mark hanging over every obesity drug.
Judge Robert Kirsch put it simply: "Clinical trials are complicated and nuanced, and investor calls are not scientific conferences." But — companies still can't mischaracterize the trial in a misleading way.
That's the line he ruled Novo may have crossed.
Novo built the entire obesity-drug category with Ozempic and Wegovy.
Now Eli Lilly is eating its lunch.
CagriSema was supposed to be Novo's answer — its next blockbuster, its proof it still leads the pack.
CEO Mike Doustdar has argued the market simply "penalized" the data too harshly.
The court isn't deciding guilt here. Just that the case is strong enough to survive.
Next stop: discovery.
Where investors get to go digging for the receipts.
That's all for now!
